Dr Ira Mellman is a leading cancer researcher, familiar to many in cancer immunotherapy for his work on the Cancer-Immunity Cycle and Cancer-Immune Set-Point with Dr Dan Chen.
Prior to joining Genentech, he spent 20 years as a faculty member at Yale, publishing extensive research on dendritic cells.
Last year, Genentech announced a strategic collaboration with Mainz based BioNTech in Germany to develop and manufacture personalized mRNA based cancer vaccines.
At the recent CRI-CIMT-EATI-AACR cancer international cancer immunotherapy conference in Mainz, Dr Mellman kindly spoke to BSB about the underlying biology/immunology, the rationale behind the BioNTech collaboration, and his vision on where he sees the potential for therapeutic cancer vaccines going forward.
This is the second post in our series on the Future of Cancer Vaccines.
Here’s a snippet of the interview with Dr Mellman to get you warmed up…